|
End-of-day quote
Shanghai S.E.
24/09/2026
|
5-day change | 1st Jan Change | ||
| 6.670 CNY | -0.89% |
|
+0.91% | +2.77% |
| Market Cap | 4.62B 688M 603M 570M 519M 972M 65.9B 979M 6.82B 2.64B 33.67B 2.58B 2.53B 108B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.83B 571M 501M 473M 431M 807M 54.7B 813M 5.66B 2.19B 27.95B 2.14B 2.1B 89.82B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
79.74% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | -0.89% | ||
| 1 week | +0.91% | ||
| Current month | -6.32% | ||
| 1 month | -4.71% | ||
| 3 months | +12.29% | ||
| 6 months | +4.06% | ||
| Current year | +2.77% |
| 1 week | 6.61 | 6.99 | |
| 1 month | 6.5 | 7.33 | |
| Current year | 5.6 | 7.45 | |
| 1 year | 5.6 | 7.45 | |
| 3 years | 4.94 | 9 | |
| 5 years | 4.94 | 11.9 | |
| 10 years | 4.5 | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 22/04/2019 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 16/05/2017 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 10/03/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 25/05/2005 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 14/05/2014 |
Wei Ren
BRD | Director/Board Member | 42 | 22/04/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.89% | +0.91% | +2.30% | -21.44% | 687M | ||
| +0.12% | +0.81% | +13.81% | +64.78% | 46.24B | ||
| +1.09% | +0.36% | +39.50% | +107.67% | 36.48B | ||
| +2.00% | +3.78% | +18.12% | +99.54% | 12.27B | ||
| +0.05% | +0.37% | -7.29% | +18.68% | 11.77B | ||
| 0.00% | 0.00% | +18.72% | +139.63% | 8.95B | ||
| -1.34% | -2.73% | +27.67% | +37.52% | 7.16B | ||
| -2.07% | -2.75% | +17.20% | +202.97% | 7.14B | ||
| +1.43% | +2.22% | +43.10% | -14.21% | 7.12B | ||
| -2.45% | -0.59% | -51.49% | +4.53% | 4.99B | ||
| Average | -0.21% | +0.36% | +12.16% | +63.97% | 14.28B | |
| Weighted average by Cap. | +0.30% | -0.27% | +19.30% | +78.70% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 400M 351M 332M 302M 566M 38.35B 570M 3.97B 1.54B 19.59B 1.5B 1.47B 62.97B | 2.24B 334M 293M 277M 252M 472M 31.98B 475M 3.31B 1.28B 16.34B 1.25B 1.23B 52.51B |
| Net income | 243M 36.15M 31.72M 29.96M 27.3M 51.11M 3.47B 51.48M 359M 139M 1.77B 136M 133M 5.69B | 320M 47.67M 41.83M 39.51M 36M 67.4M 4.57B 67.88M 473M 183M 2.33B 179M 175M 7.5B |
| Net Debt | -483M -71.94M -63.12M -59.62M -54.33M -102M -6.89B -102M -713M -276M -3.52B -270M -264M -11.32B | -784M -117M -103M -96.84M -88.25M -165M -11.2B -166M -1.16B -449M -5.72B -439M -429M -18.39B |
Employees
3,415
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/09/26 | CN¥6.670 | -0.89% | 12,962,637 |
| 23/09/26 | CN¥6.730 | -1.61% | 15,103,400 |
| 22/09/26 | CN¥6.840 | -1.58% | 19,369,600 |
| 21/09/26 | CN¥6.950 | +5.14% | 29,723,315 |
| 18/09/26 | CN¥6.610 | +0.15% | 16,252,000 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
















